A randomized trial of the duration of therapy with metronidazole plus or minus azithromycin for treatment of symptomatic bacterial vaginosis

Clinical Infectious Diseases

Volumn 44, Issue 2, 2007, Pages 213-219

  Schwebke, Jane R ^a,b   Desmond, R A ^a  

^a University of Alabama at Birmingham   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; METRONIDAZOLE;

ADULT; ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSAGE SCHEDULE COMPARISON; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; GRAM STAINING; HEADACHE; HUMAN; METALLIC TASTE; NAUSEA; NUGENT SCORE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; TASTE DISORDER; THORAX PAIN; TREATMENT DURATION; VAGINA FLORA; VAGINAL LAVAGE; VAGINAL PRURITUS; VAGINITIS; XEROSTOMIA;

ANTI-BACTERIAL AGENTS; AZITHROMYCIN; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; METRONIDAZOLE; RISK FACTORS; VAGINOSIS, BACTERIAL;

EID: 33846160165     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/509577     Document Type: Article

References (25)

1. Eschenbach DA. Bacterial vaginosis and anaerobes in obstetric-gynecologic infection. Clin Infect Dis 1993; 16:S282-7.
2. Hillier S. The vaginal microbiol ecosystem and resistance to HIV. AIDS Res Hum Retroviruses 1998; 14:17-21.
3. Hill GB. The microbiology of bacterial vaginosis. Am J Obstet Gynecol 1993; 169:450-4.
4. Nugent RP, Krohn MA, Hillier SL. Reliability of diagnosing bacterial vaginosis is improved by a standardized method of Gram stain interpretation. J Clin Microbiol 1991; 29:297-301.
5. Ferris MJ, Masztal A, Martin DH. Use of species-directed 16SrRNA gene PCR primers for detection of Atopobium vaginae in patients with bacterial vaginosis. J Clin Microbiol 2004; 42:5892-4.
6. Swidsinski A, Mendling W, Loening-Baucke V, et al. Adherent biofilms in bacterial vaginosis. Obstet Gynecol 2005; 106:1013-23.
7. Joesoef MR, Schmid GP, Hillier SL. Bacterial vaginosis: review of treatment options and potential clinical indications for therapy. Clin Infect Dis 1999; 28:557-65.
8. Spiegel CA. Susceptibility of Mobiluncus species to 23 antimicobial agents and 15 other compounds. Antimicrob Agents Chemother 1987; 31:249-52.
9. Carey JV, Blackwilder WC, Nugent RP, et al. Antepartum cultures for Ureaplasma urealyticum are not useful in predicting pregnancy outcome. Am J Obstet Gynecol 1991; 164:728-33.
10. Handsfield HH, Dalu ZA, Martin DH, Douglas JM Jr, McCarty JM, Schlossberg D. Multicenter trial of single-dose azithromycin vs. ceftriaxone in the treatment of uncomplicated gonorrhea. Sex Transm Dis 1994; 21:107-11.
11. Foulds G, Shepard RM, Johnson RB. The pharmacokinetics of azithromycin in human serum and tissues. J Antimicrob Chemother 1990; 25:73-82.
12. Amsel R, Totten PA, Spiegel CA, Chen KCS, Eschenbach D, Holmes KK. Non-specific vaginitis: diagnostic and microbial and epidemiological associations. Am J Med 1983; 74:14-22.
13. Eschenbach DA, Hillier S, Critchlow C, Stevens C, DeRouen T, Holmes KK. Diagnosis and clinical manifestations of bacterial vaginosis. Am J Obstet Gynecol 1988; 158:819-28.
14. Draper D, Parker R, Patterson E, et al. Detection of Trichomonas vaginalis in pregnant women with the InPouch TV system. J Clin Microbiol 1993; 31:1016-8.
15. Breslow N, Day N. Statistical methods in cancer research: volume I-the analysis of case control studies. IARC Sci Publ 1980; 32:5-338.
16. Lan KK, DeMets DL. Discrete sequential boundaries for clinical trials. Biometrika 1983; 70:659-63.
17. O'Brien P, Fleming T. A multiple testing procedure for clinical trials. Biometrics 1979; 35:549-56.
18. Royce R, Thorp J, Granados J, Savitz D. Bacterial vaginosis associated with HIV infection in pregnant women from North Carolina. J Acquir Immune Defic Syndr Hum Retrovirol 1999; 20:382-6.
19. Martin H, Richardson B, Nyange P, et al. Vaginal lactobacilli, microbial flora, and risk of human immunodeficiency virus type 1 and sexually transmitted disease acquisition. J Infect Dis 1999; 180:1863-8.
20. Hillier SL, Nugent RP, Eschenbach DA, et al. Association between bacterial vaginosis and preterm delivery of a low-birth weight infant. N Engl J Med 1995; 333:1737-42.
21. Eschenbach DA, Critchlow CW, Watkins H, et al. A dose duration study of metronidazole for the treatment of non-specific vaginosis. Scand J Infect Dis Suppl 1983; 40:73-80.
22. Schwebke J, Desmond, R. Risk factors for bacterial vaginosis in women at high risk for STDs. Sex Transm Dis 2005; 32:654-8.
23. Sanchez S, Garcia PJ, Thomas KK, Catlin M, Holmes KK. Intravaginal metronidazole gel versus metronidazole plus nystatin ovules for bacterial vaginosis: a randomized controlled trial. Am J Obstet Gynecol 2004; 191:1898-906.
24. Smart SA, Mindel A. Social and sexual risk factors for bacterial vaginosis. Sex Transm Infect 2004;80:58-62.
25. Bradshaw CS, Morton AN, Hocking J, et al. High recurrence rates of bacterial vaginosis over the course of 12 months after oral metronidazole therapy and factors associated with recurrence. J Infect Dis 2006; 193:1475-7.